156969-42-5

Basic information

• Product Name: PYRAZOLO[1,5-A]PYRIDIN-5-OL
• Synonyms: PYRAZOLO[1,5-A]PYRIDIN-5-OL
• CAS NO: 156969-42-5
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Mol File: 156969-42-5.mol

Chemical Properties

• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 6.53±0.53(Predicted)
• CAS DataBase Reference: PYRAZOLO[1,5-A]PYRIDIN-5-OL(CAS DataBase Reference)
• NIST Chemistry Reference: PYRAZOLO[1,5-A]PYRIDIN-5-OL(156969-42-5)
• EPA Substance Registry System: PYRAZOLO[1,5-A]PYRIDIN-5-OL(156969-42-5)

Safety Data

• Hazardous Substances Data: 156969-42-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrazolo[1,5-a]pyridin-5-ol is used as a medicinal drug for its sedative and anxiolytic properties, primarily targeting the treatment of anxiety and insomnia. It modulates the GABA-A receptor complex through its action as a positive modulator of the benzodiazepine receptor, thereby influencing the central nervous system to alleviate symptoms of anxiety and promote sleep.
However, it is important to note that the use of Pyrazolo[1,5-a]pyridin-5-ol has been limited due to concerns regarding its safety and the potential for abuse. Further research and development are necessary to optimize its therapeutic applications while mitigating these risks.

Upstream product

• 1453-58-3 3-Methylpyrazole 
• 471-25-0 Propiolic acid 
• 156969-32-3 3-methyl-1-propynoylpyrazole 
• 156969-33-4 5-methyl-1-propynoylpyrazole 
• 866216-17-3 methyl 5-benzyloxypyrazolo[1,5-a]pyridine-3-carboxylate 
• 99446-31-8 5-methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid methyl ester 
• 620-08-6 4-methoxypyridine 
• 143281-49-6 1-amino-4-methoxypyridinium iodide 
• 99446-53-4 ethyl 5-methoxypyrazolo[1,5-a]pyridine-3-carboxylate 
• 49826-70-2 4-(benzyloxy)pyridine 

Downstream Products

• 866216-29-7 (1R,2S,5R)-menthyl (5R)-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrid-5-yl)carbamate 
• 877994-06-4 5-methoxypyrazolo[1,5-a]pyridine 
• 1033810-58-0 5-(2-chloro-4-nitrophenoxy)pyrazolo[1,5-a]pyridine 
• 1101118-13-1 N'-((5-methoxypyrazolo[1,5-a]pyridin-3-yl)methylene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1101118-14-2 3-((2-methyl-2-(2-methyl-5-nitrophenylsulfonyl)-hydrazono)methyl)pyrazolo[1,5-a]pyridin-5-yl acetate 
• 1101118-15-3 N'-((5-hydroxypyrazolo[1,5-a]pyridin-3-yl)methylene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 104468-87-3 pyrazolo [1,5-a]pyridine-5-carboxylic acid 
• 1453174-08-7 pyrazolo[1,5-a]pyridine-5-carboxylic acid 4-(piperidine-1-sulfonyl)benzylamide 
• 1060725-03-2 5-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine 
• 1060725-77-0 5-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine-3-carbaldehyde 
• 1060726-55-7 (E)-5-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine-3-carbaldehyde oxime 
• 1060726-68-2 5-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine-3-carbonitrile 

Relevant articles and documents

Efficient salt-induced kinase inhibitor and preparation method thereof

The invention discloses an efficient salt-induced kinase inhibitor and a preparation method thereof, and the efficient salt-induced kinase inhibitor is characterized by comprising substances of a chemical formula in the invention. The salt-induced kinase inhibitor with excellent performance has high inhibitory activity for in-vitro experiments and also has high cell inhibitory activity.

Functionally selective dopamine D2, D3 receptor partial agonists

Dopamine D2 receptor-promoted activation of Gαo over Gαi may increase synaptic plasticity and thereby might improve negative symptoms of schizophrenia. Heterocyclic dopamine surrogates comprising a pyrazolo[1,5-a]pyridine

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,

Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors

We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110α isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a]pyridine ring system, and found compound 5x to be a particularly potent example (p110α IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model.

PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY

Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

Indolizines and aza-analog derivatives thereof as CNS active compounds

Presently disclosed are indolicine-based compounds of the general formula which have medical utility, for example as antipsychotics.

Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists

Taking advantage of a 3D-QSAR based pharmacophore hypothesis, synthesis and biological evaluation of dopaminergic 5-aminotetrahydropyrazolo[1,5-a]pyridines are described. The data displayed substantial and selective D3 receptor affinity for the heterocycl